Company news

BioRestorative Therapies, Inc. news in 2024

BioRestorative Therapies, Inc.'s news releases, calls and decks from 2024, newest first.

View company

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

December 4, 2024

BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

November 20, 2024

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

November 12, 2024

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium

November 5, 2024

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

November 4, 2024

BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program

October 30, 2024

BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

September 18, 2024

BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update

August 12, 2024

BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024

August 5, 2024

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

June 26, 2024

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

June 16, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 23, 2024

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 14, 2024

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 13, 2024

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

May 7, 2024

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

April 29, 2024

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

April 29, 2024

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

April 15, 2024

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

April 7, 2024

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

April 2, 2024

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

March 31, 2024

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

February 5, 2024

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

February 4, 2024

Calls in 2024

Decks in 2024